60

Tonghua Dongbao Pharmaceutical Co LtdSHG 600867 Stock Report

Last reporting period 30 Jun, 2024

Updated 22 Oct, 2024

Last price

Market cap $B

2.114

Small

Exchange

XSHG - Shanghai Stock Exchange

600867.SS Stock Analysis

60

Uncovered

Tonghua Dongbao Pharmaceutical Co Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

79/100

Moderate score

Market cap $B

2.114

Dividend yield

5.00 %

Shares outstanding

1 982.08 B

Tonghua Dongbao Pharmaceutical Co., Ltd. is engaged in the manufacture, distribution, research and development of pharmaceuticals. The company is headquartered in Tonghua, Jilin and currently employs 2,814 full-time employees. The firm provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The firm's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The firm also provides medical instruments, plastic-steel windows and profiles, and operates property business. The firm distributes its products within domestic markets and to overseas markets.

View Section: Eyestock Rating